Subscribe

Subscribe to Our Newsletter

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks
Biotechnology Pharmaceuticals Stock Market Investment Analysis Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Overweight Rating from Cantor Fitzgerald

Newsdesk profile image
by Newsdesk
Updated
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Overweight Rating from Cantor Fitzgerald

AI-Generated Summary

Cantor Fitzgerald has reiterated an "overweight" rating on Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company, setting a $105 price target. This follows similar positive ratings from other analysts, leading to an average target price of $81.50. The company recently reported better-than-expected Q2 earnings, though it operates with negative margins.

In a nutshell

This article provides a comprehensive overview of financial analyst sentiment and key financial metrics for Ultragenyx Pharmaceutical. It offers readers, particularly those interested in biopharmaceutical investments, a snapshot of the company's market standing and recent performance indicators.

Source: ETF Daily News

Newsdesk profile image
by Newsdesk
Updated

Be informed!

Rx.news delivers critical healthcare intelligence to pharmaceutical professionals, biotech innovators, healthcare investors, medical practitioners, and policy makers.

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks

Read More